Creative Planning raised its holdings in Illumina, Inc. (NASDAQ:ILMN) by 9.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,384 shares of the life sciences company’s stock after acquiring an additional 1,107 shares during the period. Creative Planning’s holdings in Illumina were worth $2,706,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also bought and sold shares of ILMN. Winslow Capital Management LLC acquired a new position in Illumina in the second quarter valued at about $211,584,000. Fred Alger Management Inc. grew its stake in Illumina by 611.9% in the second quarter. Fred Alger Management Inc. now owns 637,597 shares of the life sciences company’s stock valued at $110,636,000 after acquiring an additional 548,030 shares during the period. Capital World Investors grew its stake in Illumina by 23.8% in the second quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock valued at $370,465,000 after acquiring an additional 410,000 shares during the period. Janus Henderson Group PLC grew its stake in Illumina by 1,556.2% in the second quarter. Janus Henderson Group PLC now owns 330,010 shares of the life sciences company’s stock valued at $57,263,000 after acquiring an additional 310,084 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in Illumina in the second quarter valued at about $47,010,000. 91.63% of the stock is owned by hedge funds and other institutional investors.
Illumina, Inc. (NASDAQ ILMN) opened at $245.19 on Tuesday. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $35,800.00, a PE ratio of 46.26, a PEG ratio of 3.27 and a beta of 0.79. Illumina, Inc. has a 52-week low of $156.50 and a 52-week high of $248.97.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, beating the consensus estimate of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The firm had revenue of $714.00 million during the quarter, compared to analysts’ expectations of $692.77 million. During the same period in the prior year, the firm posted $0.97 earnings per share. The business’s quarterly revenue was up 17.6% compared to the same quarter last year. research analysts anticipate that Illumina, Inc. will post 3.77 EPS for the current fiscal year.
A number of research analysts have issued reports on ILMN shares. Citigroup boosted their target price on Illumina from $180.00 to $220.00 and gave the company a “neutral” rating in a research note on Wednesday, October 25th. Robert W. Baird raised Illumina from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $184.00 to $228.00 in a research note on Wednesday, October 25th. Zacks Investment Research cut Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, December 26th. Cowen boosted their target price on Illumina from $250.00 to $275.00 and gave the company an “outperform” rating in a research note on Monday. Finally, Barclays upped their price objective on Illumina from $150.00 to $185.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 25th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $223.88.
In related news, SVP Oene Mark Van sold 1,250 shares of the stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $207.76, for a total transaction of $259,700.00. Following the completion of the transaction, the senior vice president now directly owns 11,691 shares of the company’s stock, valued at $2,428,922.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Marc Stapley sold 2,000 shares of the stock in a transaction that occurred on Thursday, October 26th. The shares were sold at an average price of $206.88, for a total value of $413,760.00. Following the transaction, the executive vice president now directly owns 34,579 shares of the company’s stock, valued at $7,153,703.52. The disclosure for this sale can be found here. Insiders have sold 134,671 shares of company stock valued at $29,417,628 over the last three months. Insiders own 0.89% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://ledgergazette.com/2018/01/23/illumina-inc-ilmn-shares-bought-by-creative-planning.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.